Social media

Drive market access success with payer analytics from Symphony Health, an ICON plc company. As you finalise your 2025 budget, invest in insights that matter. Symphony Health’s payer-focused solutions help you: • Underst...

Unlock market access insights before year-end. As you plan your remaining 2025 budget, consider a strategic investment: payer analytics from Symphony Health, an ICON plc company. Our solutions help you understand how co...

ICON’s Centre for Pediatric Clinical Development team is a proud supporter of World Children’s Day. Stay up to date on the latest information and insights in pediatric clinical research. Learn more: https://ow.ly/MHam50X...

This year’s theme for World Children’s Day is "Listen to the future, stand up for children's rights”. ICON is invested in bringing safe, effective, pediatric-tested treatments to children all over the world. In the past ...

PubsHub Journals & Congresses includes built-in screening to help safeguard authors from predatory journals and congresses. With rigorous checks and trusted data, the system helps ensure your work is submitted to credibl...

PubsHub Journals & Congresses includes built-in screening to help safeguard authors from predatory journals and congresses. With rigorous checks and trusted data, the system helps ensure your work is submitted to credibl...

In recognition of World Children’s Day, ICON’s Patient Centred Outcomes (PCO) team proudly reaffirms its commitment to improving the lives of children and families facing complex health challenges. Our dedicated team of ...

For the second article in our new series, we delve deeper into ISO 14971 (Application of risk management to medical devices). We discuss a history of risk-based thinking and common misunderstandings around risk analysis ...

For the second article in our new series, we delve deeper into ISO 14971 (Application of risk management to medical devices). We discuss a history of risk-based thinking and common misunderstandings around risk analysis ...

What separates winners from laggards in drug development is recognising the macro trends in the regulatory environment at the highest level of the company and formulating strategies to deliver; - Agility in regulatory st...

What separates winners from laggards in drug development is recognising the macro trends in the regulatory environment at the highest level of the company and formulating strategies to deliver; - Agility in regulatory st...

In this blog from Prof. Peter Schueler, MD, he explores how biomarker innovation is accelerating progress in Alzheimer’s, Parkinson’s, and other CNS trials - bringing new precision, speed, and clarity to a historically c...